Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dupilumab - Regeneron/Sanofi

Next Previous
Drug Profile

Dupilumab - Regeneron/Sanofi

Alternative Names: Dupilumab-Sanofi/Regeneron; Dupixent; REGN-668; SAR-231893

Latest Information Update: 09 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals; sanofi-aventis
  • Developer Aimmune Therapeutics; Mayo Clinic; Regeneron Pharmaceuticals; Sanofi; Sanofi-Aventis GmbH
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antifungals; Antineoplastics; Antipruritics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 13 receptor antagonists; Interleukin 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bullous pemphigoid; Eosinophilic oesophagitis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Asthma; Atopic dermatitis; Chronic obstructive pulmonary disease; Chronic urticaria; Eosinophilic oesophagitis; Prurigo nodularis; Rhinosinusitis
  • Registered Bullous pemphigoid
  • Phase III Pruritus; Wheezing
  • Phase II/III Eosinophilic gastroenteritis
  • Phase II Aspergillosis; Eczema; Prostate cancer
  • No development reported Allergic asthma
  • Discontinued Grass pollen hypersensitivity; Peanut hypersensitivity; Ulcerative colitis

Most Recent Events

  • 27 Feb 2026 Preregistration for Chronic-urticaria (In children) in European Union (SC) before February 2026
  • 27 Feb 2026 Preregistration for Chronic-urticaria (In children) in USA (SC) before February 2026
  • 27 Feb 2026 Regeneron Pharmaceuticals anticipates a final decision for from EC for Chronic urticaria (In children) in the coming months in 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top